Drugs / CC-98633
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04394650 | Aug 2020 → Jul 2024 | plasma cell myeloma | Juno Therapeutics, a Subsidiary of Celgene | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-98633 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04394650 ↗ |
| Modality | Cell therapy | “BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells” NCT04394650 ↗ |
| Route | Intravenous | “one dose of CC-98633 administered by intravenous (IV) injection” NCT04394650 ↗ |